StreetInsider.com News Articles

Form 8-K Marker Therapeutics, For: Oct 19

Mon, 19 Oct 2026 07:13:00 -0400

si-local-file:///var/storage/secattach/20261019/27200566.html

Marker Therapeutics gets $2.6M FDA grant for pancreatic cancer therapy

Mon, 19 Oct 2026 07:00:15 -0400

Marker Therapeutics, Inc. (Nasdaq: MRKR) has received a $2.6 million grant from the U.S. Food and Drug Administration through its Orphan Products Clinical Trials grants program to fund a Phase 1 clinical study of MT-601, its lead investigational T cell therapy, in patients with locally advanced unresectable pancreatic cancer.

The FDA's Orphan Products Clinical Trials grants program received 66 applications in fiscal year 2026 and selected six projects for funding. Applications undergo scientific peer review evaluating scientific rationale, clinical trial design, feasibility, and potential contribution to product development.

MT-601 is a non-genetically modified multi-antigen recognizing (MAR) T cell therapy that targets six

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Mon, 19 Oct 2026 07:00:00 -0400

Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform

HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded $2.6 million from the U.S. Food and Drug Administration (FDA) through its Orphan Products Clinical Trials grants program. The funding will support a Phase 1 clinical study evaluating the Company’s lead investigational MAR-T

Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer

Mon, 19 Oct 2026 07:00:00 -0400

Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform

Marker Therapeutics notes expanded CDMO after Kincellis formation

Tue, 22 Sep 2026 08:03:18 -0400

Marker Therapeutics, Inc. (NASDAQ: MRKR) highlighted the expanded manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of its existing manufacturing partner, Cellipont Bioservices, with Kincell Bio to form Kincellis Advanced Therapies.

Kincellis was formed on Sept. 17, 2026, creating a U.S.-based contract development and manufacturing organization with approximately 140,000 square feet of development and manufacturing infrastructure and 16 operational, qualified GMP manufacturing suites across three U.S. locations in Gainesville, Florida; Research Triangle Park, North Carolina; and The Woodlands, Texas.

Marker previously selected Cellipont Bioservices as its manufacturing partner for MT-601 to support continued clinical development and potential pivotal-stage and

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

Tue, 22 Sep 2026 08:00:00 -0400

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for the treatment of hematologic malignancies and solid tumors, today highlighted the expanded infrastructure, technical expertise and manufacturing capabilities supporting its lead program, MT-601 (neldaleucel), following the combination of Cellipont Bioservices and Kincell Bio to form Kincellis Advanced Therapies.

Marker previously selected Cellipont Bioservices as its manufacturing partner for MT-601 (neldaleucel) to support the continued clinical development and prepare for potential pivotal-stage and commercial manufacturing requirements.

Kincellis was formed through the

Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies

Tue, 22 Sep 2026 08:00:00 -0400

Kincellis was formed through the

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Fri, 21 Aug 2026 07:04:39 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "On August 14, Marker Therapeutics filed its 2Q26 10-Q, which reiterates that the Cellipont Bioservices technology transfer is being advanced in anticipation of the commencement of Marker's larger pivotal lymphoma trial potentially in 2026. We continue to expect FDA feedback on the planned pivotal Phase 2b design for Marker's lead multi-antigen recognizing (MAR)-T cell product MT-601 in diffuse large B-cell lymphoma (DLBCL) to emerge in 2H26; Baylor College of Medicine (BCM) continues to supply MAR-T cell products, including MT-601, for

Form 10-Q Marker Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931818.html

Form 10-Q Marker Therapeutics, For: Jun 30

Fri, 14 Aug 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260814/26931818.html

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Fri, 10 Jul 2026 06:51:16 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "On June 30, we hosted a fireside chat with Marker Therapeutics' CEO Juan Vera, M.D., at H.C. Wainwright’s 4th Annual Cell Therapy Virtual Conference (June 30 to July 1). Our discussion focused on Marker's lead cell therapy program MT-601 being developed in lymphoma and pancreatic cancer, reinforcing our core investment thesis centered on Marker's Multi-Antigen Recognizing (MAR)-T cell therapy platform. MAR-T cells are a distinct modality from chimeric antigen receptor (CAR-T) cell therapy approaches. In contrast to CAR-T cells, MAR-T

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Wed, 20 May 2026 06:49:15 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "Marker reported 1Q26 financial results on May 15. The quarter was not thesis-changing, but it was supportive of the catalyst setup into 2Q26, in our view, as Marker maintained tight cost control, reported just $1.4 million of operating cash use, and exited 1Q26 with $15.6 million in cash, cash equivalents, and restricted cash, supporting runway into 1Q27 assuming no additional grant funds are received. The key stock debate remains clinical and regulatory: whether MT-601 can move from the Phase 1

Form 10-Q Marker Therapeutics, For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507513.html

Form 10-Q Marker Therapeutics, For: Mar 31

Fri, 15 May 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260515/26507513.html

Form 8-K Marker Therapeutics, For: May 01

Mon, 04 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260504/26426368.html

Form 8-K Marker Therapeutics, For: May 01

Mon, 04 May 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260504/26426368.html

H.C. Wainwright Reiterates Buy Rating on Marker Therapeutics (MRKR)

Mon, 23 Mar 2026 06:48:08 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $10.00 price target on Marker Therapeutics (NASDAQ: MRKR).

The analyst commented: "On Mar 18, Marker reported 4Q25 and 2025 financial results and provided a corporate update on its multi-antigen recognizing T cell (MAR-T) pipeline—a non-genetically modified autologous T cell therapy product targeting multiple tumor-associated antigens (TAAs). Importantly, the upcoming meeting with the FDA anticipated expected in 2Q26 (around April according to our January meeting with management) is the primary gating factor for Marker’s transition towards pivotal-stage. Marker plans to discuss the details for the planned pivotal Phase 2b study to evaluate

Form DEFA14A Marker Therapeutics,

Fri, 20 Mar 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260320/26197796.html

Form DEFA14A Marker Therapeutics,

Fri, 20 Mar 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260320/26197796.html

Form ARS Marker Therapeutics, For: Dec 31

Fri, 20 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260320/26197780.html

Form ARS Marker Therapeutics, For: Dec 31

Fri, 20 Mar 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260320/26197780.html

Form DEF 14A Marker Therapeutics, For: May 01

Fri, 20 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260320/26197744.html

Form DEF 14A Marker Therapeutics, For: May 01

Fri, 20 Mar 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260320/26197744.html

Form 8-K Marker Therapeutics, For: Mar 18

Thu, 19 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260319/26188455.html

Form 8-K Marker Therapeutics, For: Mar 18

Thu, 19 Mar 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260319/26188455.html